Offers a patented strain of Limosilactobacillus reuteri DSM 17648 (previously Lactobacillus) to support healthy levels of H. pylori. This strain is considered a postbiotic (a preparation of dead cells and metabolites that can act as a biological response modifier).

PyloGuard™ is a dietary supplement designed to support the body’s natural processes for elimination. It contains patented Lactobacillus reuteri DSM17648, which can attract specific organisms in the intestine and support their removal via the digestive tract. This particular strain of L. reuteri maintains H. pylori levels already within the normal range and supports overall digestive health.

At a glance

PyloGuard™ is a dietary supplement designed to support the body’s natural processes for elimination. It contains patented Lactobacillus reuteri DSM17648, which can attract specific organisms in the intestine and support their removal via the digestive tract. This particular strain of L. reuteri maintains H. pylori levels already within the normal range and supports overall digestive health.

Key Benefits:
  • Supports bacteria levels in the stomach
  • Promotes the body’s process of elimination
  • Supports the microbiome
  • Maintains H pylori levels already within the normal range
Key Features:
  • Lactobacillus reuteri DSM17648 culture containing ≥ 1 x1011 inactivated cells/gram
  • Produced in a low-temperature fermentation & drying process to avoid denaturing
  • Stable under the gastric conditions
  • Doesn’t disturb the gut microbial balance
  • Formulated in a free-flowing, spray-dried powder format
  • Stable at room temperature
  • Backed by in vitro and in vivo scientific research
  • Safe for long-term daily use (QPS, MIC, GRAS)
  • Produced and tested to exceed the most stringent EU quality standards (ISO)
  • Free from GMO, lactose, and fructose

What is Helicobacter Pylori?

Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped bacterium native to the human gastrointestinal (GI) tract. It has an affinity for the acidic environment of the gastric mucosa. Estimates say that up to 50% of the world’s population carries H. pylori in their GI tracts. H. pylori is spread through direct contact with individuals or household pets through saliva, feces, or contaminated food or water.

Humanity’s relationship with H. pylori is ambiguous. H. pylori can have a commensal or symbiotic relationship with its human host.

H. pylori colonizes and multiplies in the duodenum and gastric mucosa, secreting urease, the enzyme that converts urea to ammonia. Alkaline ammonia buffers the naturally low pH of the stomach, providing the optimal environment for H. pylori to live.


Disruption of the microbiome can cause occasional:

  • Nausea
  • Heartburn
  • Loss of appetite
  • Dyspepsia

Dosing Instructions

Ages 9+: Open 1 capsule into 8 oz of water and drink once daily on an empty stomach. Children under the age of 9, please consult your healthcare practitioner.

Immune Support Studies:

Form/Duration

Study Details and Results

Reference

Pylopass® (PyloGuard™)

28 days and 56 days

Placebo-controlled trial 103

participants, children 9-17 years

Supported ammonia levels in

Pylopass® (PyloGuard™) group

Pylopass® (PyloGuard™) group reported higher rate of abdominal relief and reduced incidence of diarrhea

DOI: 10.15406/ghoa.2020.11.00407

Pylopass® (PyloGuard™)

2 weeks

Pilot study 27 participants

DSM17648 co-aggregates with human strain of H. pylori without aggregating with any other

commensal bacteria.

Supplementation supported levels of H. pylori.

DOI: 10.1007/s12602-014-9181-3

Pylopass® (PyloGuard™)

4 weeks

Placebo-controlled, single-blind study 24 participants

Supported H.pylori levels and improvement of abdominal discomfort

DOI: 10.1186/s40795-018-0257-4

Immune Support Studies Continued:

Form/ Duration

Study Details and Results

References

Pylopass® (PyloGuard™)

2 weeks


Placebo controlled study 22

participants

Supported H. pylori levels

Effect still observed 6 months after end of supplementation

DOI: 10.3390/nu5083062

Pylopass® (PyloGuard™)

4 weeks


Randomized, double blind,

placebo-controlled clinical study 200 participants

Significant improvement of

side effects compared to placebo group

Promoted abundance of

Fusicatenibacter, Subdoligranulum, and Faecalibacterium

Mean GSRS score decreased significantly in the LR group as

compared with the placebo group

DOI: doi.org/10.1111/hel.12856

Pylopass® (PyloGuard™)

2 weeks


90 participants Prospective and interventional randomized, double-center study. 86% eradication rate in Pylopass® (PyloGuard™) group.

20% higher eradication rate compared to standard therapy group. Significant reduction in symptoms compared to standard therapy group.

DOI: 10.9734/JPRI/2021/v33i52B33611

 

Product Disclaimer

At CityMed Pharmacy, we strive for accuracy in our product images and information. However, manufacturers may make changes to product packaging or ingredients that are not yet reflected on our site. We recommend that you read the labels, warnings, and directions on purchased products before use and not rely solely on the information provided by CityMed Pharmacy.